A Jayanthan, S Howard, T Trippet, TM Horton, L Daisley, & A Narendran. Targeting the Bcl-2 family of proteins in Hodgkin Lymphoma: In vitro cytotoxicity, target modulation and drug combination studies of the BH3 mimetic ABT-737. Leukemia and Lymphoma, 2009. 50:1174-82. PMID: 19557638
JA Muscal, PA Thompson, VL Geranda, BD Dayton, J Bauch, TM Horton, L McGuffey, JG Nuchtern, RC Dauser, BW Gibson, SM Blaney and JM Su. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother. Pharmacol. 2009. In press. PMID: 19526240
TM Horton, G Jenkins, D Pati, L Zhang, MD Dolan, A Ribes-Zamora, AA Bertuch, SM Blaney, SL Delaney, M Hegde and SL Berg. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009. 8:2232-42. PMID: 19671751
TM Horton, R Sposto, P Brown, CP Reynolds, SP Hunger, NJ Winick, AE Raetz, WL Carroll, RJ Arceci, MJ Borowitz, PS Gaynon, L Gore, S Jeha, BJ Maurer, WE Siegel, A Biondi, PR Kearns, A Narendran, LB Silverman, MA Smith, CM Zwaan JA Whitlock. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference. Pediatric Blood and Cancer. 2009. In press.
TM Horton, D Pati, SE Plon, PA Thompson, LR Bomgaars, PC Adamson, AM Ingle, J Wright, AH Brockman, M Paton, SM Blaney. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia; A Children’s Oncology Group study. Clin. Cancer Res. 2007. 13: 1516-22.
TM Horton, PA Thompson, SL Berg, PC Adamson, AM Ingle, E Dolan, M Hedgi, and SM Blaney. A Phase 1 Trial of Temozolomide in Pediatric Patients with Refractory/Recurrent Leukemias: A Children’s Oncology Group Study. J. Clin. Oncol. 2007. 25:4922-8.
TM Horton, SE Plon, A Gannavarapu, SM Blaney, D D’Argenio, SL Berg. Bortezomib potentiation of chemotherapy agents in acute leukemia in vitro. Cancer Chemotherapy and Pharmacology. 2006. 58: 13-23.
TM Horton, MM Ames, JM Reid, MD Krailo, T Pendergrass, SP Ivy, R Mosher, GH Reaman, N Seibel. Paclitaxel for Treatment of Refractory Leukemia in Children: A Phase 1 Study of the Children’s Oncology Group. Pedi. Blood and Cancer. 2007,50(4):788-92.
DJ Min, NP Moskowitz, C Brownstein, H Lee, TM Horton, and WL Carroll. Diverse Pathways Mediate Chemotherapy-Induced Cell Death in Acute
Lymphoblastic Leukemia Cell Lines. Apoptosis. 2006. 11:1977-86.
TM Horton, SE Plon, A Gannavarapu, SM Blaney, D D’Argenio, SL Berg. Bortezomib potentiation of chemotherapy agents in acute leukemia in vitro. Cancer Chemotherapy and Pharmacology.
TM Horton, SM Blaney, A-M langevini, J Kuhn, B kamen, SL Berg, M Berstein, S Weitman. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: A pediatric oncology group study. Clin. Cancer Res.2005. 11:1884-1889.
MN Suell, TM Horton, MK Dishop, DH Mahoney, OO Olutoye, BU Mueller. Outcomes for children with gallbladder abnormalities and sickle cell disease. J. Pediatrics. 2004. 145:617-621.
SM Blaney, M Bernstein, K Neville, J Ginsberg, B. Kitchen, TM Horton, SL Berg, M Krailo, PC Adamson. A Phase 1 study of the proteasome inhibitor PS-341 in pediatric patients with refractory solid tumors: A Children’s Oncology Group study. J Clin Oncol.2004. 22:4752-4757.
TM Horton, JD Stone, D Yee, Z Dreyer, JL Moake, DH Mahoney. A case series of thrombotic thrombocytopenic purpura (TTP) in children and adolescents. J. Ped. Hematol.Oncol. 2003. 25:336-339.
Pease, CL, TM Horton, K McClain, S Kaplan. Aseptic meningitis in a child following systemic treatment with high-dose cytarabine. Ped. Infect. Dis. J. 2001 20:87-89.
Horton TM, JA Petros, A Heddi, JM Shoffner, K Houponon, SD Graham, T Gramlich, and DC Wallace. A novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes, Chromosomes and Cancer. 1996. 5:1-7.